Steve,No hiccup. The Dubai decision was made due to the TGA...

Steve,

No hiccup. The Dubai decision was made due to the TGA dragging it's feet around licensing the export of CVac out of Australia. It would have taken over a year, and management couldn't rely on their apheresis business to cover costs there for that long. Pull the pin, save money, concentrate on CVac.
Nothing to do with CVac itself, or its profitability.

Dubai would not have helped the approval process. FDA would not take into account anything that wasn't part of the trial. Strict process must be adhered to, Dubai was outside of that.
The positives of Dubai would have been predominantly to the patients and the company itself - As a pilot commercialisation they could streamline their processes and get rid of any gremlins before getting approval and going global.
On a shareholder level, I hoped that it would also leak anecdotal efficacy results (via patients) ahead of the phase 3 completion as a boost to SP.

alptrade,
Calling Cripto-1 development a 'bad decision' is a bit rough don't you think?
If every biotech company didn't attempt breakthrough science because they were afraid it might not work, nothing would ever get done. Cripto-1 technology may yet still have benefits, but Prima are going to let other companies find out how best to use it. Their focus is on development.

In my view, the cancellation of the Cripto-1 program bodes well for CVac.
It says they're the type of company that won't drag out a product development if they don't believe it will work in the way the want. They've not cancelled CVac, so they must be confident in it.